December 10, 2024 | In this episode of The Chain, host Andrew Bradbury, CSO of Specifica, an IQVIA business, speaks with Randolph Lopez, CTO and co-founder of A-Alpha Bio, about how A-Alpha Bio is changing the game of protein-protein interactions with their platform AlphaSeq. Lopez delves into the origins, the process, the successes, and the possibilities of the company’s platform and how it can help with epitope mapping, affinity predictions, and off-target binding. With the data the platform generates, Lopez also discusses how this affects the potential of AI and ML.

GUEST BIO

Randolph Lopez, PhD, CTO and Co-Founder, A-Alpha Bio
Randolph Lopez is the CTO and Co-Founder of A-Alpha Bio, a start-up focused on the discovery and optimization of biologics therapeutics, massive protein-protein interaction datasets, and machine learning. Prior to A-Alpha Bio, Randolph did his graduate work at the University of Washington where he pioneered research in synthetic biology, molecular computing, and DNA information storage.

MODERATOR BIO

Andrew R.M. Bradbury, MD, PhD, CSO, Specifica, an IQVIA business
Andrew Bradbury is Chief Scientific Officer of Specifica. He trained in medicine at the universities of Oxford and London and received his PhD from the university of Cambridge at the MRC Laboratory of Molecular Biology under the guidance of Nobel Laureate, Cesar Milstein. He has worked in the fields of phage and yeast display, library generation, antibody engineering and Next Generation Sequencing for over thirty years. He was a Group Leader at Los Alamos National Laboratory before founding Specifica. Specifica's mission is to enable companies developing therapeutic antibodies with the world’s best antibody discovery platform.